These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 12428082)

  • 21. Laboratory detection of 'aspirin resistance': what test should we use (if any)?
    Cattaneo M
    Eur Heart J; 2007 Jul; 28(14):1673-5. PubMed ID: 17586540
    [No Abstract]   [Full Text] [Related]  

  • 22. Aspirin resistance: current concepts.
    Mason PJ; Freedman JE; Jacobs AK
    Rev Cardiovasc Med; 2004; 5(3):156-63. PubMed ID: 15346099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.
    Mathewkutty S; McGuire DK
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):541-9. PubMed ID: 19419262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A critical appraisal of the phenomenon of aspirin resistance.
    Svenstrup Poulsen T; Kristensen SR; Atar D; Mickley H
    Cardiology; 2005; 104(2):83-91. PubMed ID: 16020925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin.
    Undas A; Placzkiewicz-Jankowska E; Zieliński L; Tracz W
    Thromb Haemost; 2007 Jun; 97(6):1056-8. PubMed ID: 17549314
    [No Abstract]   [Full Text] [Related]  

  • 26. [Cyclooxigenase-1 gene polymorphism and aspirin resistance].
    Bondar' TN; Kravchenko NA
    Tsitol Genet; 2012; 46(4):66-72. PubMed ID: 23074965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological control of platelet function.
    Clutton P; Folts JD; Freedman JE
    Pharmacol Res; 2001 Oct; 44(4):255-64. PubMed ID: 11592859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aspirin resistance.
    Tantry US; Mahla E; Gurbel PA
    Prog Cardiovasc Dis; 2009; 52(2):141-52. PubMed ID: 19732606
    [No Abstract]   [Full Text] [Related]  

  • 29. Letter by Wallace and Chan regarding article, "Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin".
    Chan MV; Wallace JL
    Circulation; 2013 Sep; 128(12):e190. PubMed ID: 24043152
    [No Abstract]   [Full Text] [Related]  

  • 30. Letter by Dillinger et al regarding article, "Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin".
    Dillinger JG; Drouet L; Henry P
    Circulation; 2013 Sep; 128(12):e189. PubMed ID: 24043151
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical importance of antiplatelet drugs in cardiovascular diseases.
    Papp J; Kenyeres P; Toth K
    Clin Hemorheol Microcirc; 2013; 53(1-2):81-96. PubMed ID: 22954637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prevalence, risk factors and prognosis of aspirin resistance in elderly male patients with cardiovascular disease.
    Cao J; Liu L; Fan L; Chen T; Hu G; Hu Y; Zhu B; Li J; Wang H; Li X
    Aging Male; 2012 Sep; 15(3):140-7. PubMed ID: 22452804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients.
    Crescente M; Di Castelnuovo A; Iacoviello L; de Gaetano G; Cerletti C
    Thromb Haemost; 2008 Jun; 99(6):1129-31. PubMed ID: 18521524
    [No Abstract]   [Full Text] [Related]  

  • 34. Mechanisms of aspirin resistance.
    Floyd CN; Ferro A
    Pharmacol Ther; 2014 Jan; 141(1):69-78. PubMed ID: 23993980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
    Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
    Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to letters regarding article, "Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin".
    Grosser T; Fries S; Lawson JA; Kapoor SC; Grant GR; Fitzgerald GA
    Circulation; 2013 Sep; 128(12):e191. PubMed ID: 24043153
    [No Abstract]   [Full Text] [Related]  

  • 37. The aspirin resistance controversy: clinical entity or platelet heterogeneity?
    Freedman JE
    Circulation; 2006 Jun; 113(25):2865-7. PubMed ID: 16801473
    [No Abstract]   [Full Text] [Related]  

  • 38. Antiplatelet therapies: aspirin at the heart of new directions.
    Bunimov N; Laneuville O
    Cardiovasc Hematol Disord Drug Targets; 2013 Dec; 13(3):173-84. PubMed ID: 24479717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmazie in unserer Zeit 4/2009].
    Alban S; Dingermann T
    Pharm Unserer Zeit; 2009; 38(4):295. PubMed ID: 19572344
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug insight: aspirin resistance-fact or fashion?
    Maree AO; Cox D; Fitzgerald DJ
    Nat Clin Pract Cardiovasc Med; 2007 Mar; 4(3):E1; author reply E2. PubMed ID: 17330121
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.